Publications by authors named "Daniel Moj"

Claim this Profile
A
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Xia Li, Sebastian Frechen, Daniel Moj, Thorsten Lehr, Max Taubert

Clin Pharmacokinet· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.
Daniel Moj, Hugo Maas, André Schaeftlein, Nina Hanke, José David Gómez-Mantilla

Clin Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Nina Hanke, Sebastian Frechen, Daniel Moj, Hannah Britz, Thomas Eissing

CPT Pharmacometrics Syst Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.
Nadine Schaefer, Daniel Moj, Thorsten Lehr, Peter H Schmidt, Frank Ramsthaler

Int J Legal Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Nina Hanke, Michael Teifel, Daniel Moj, Jan-Georg Wojtyniak, Hannah Britz

Cancer Chemother Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
Daniel Moj, Hannah Britz, Jürgen Burhenne, Clinton F Stewart, Gerlinde Egerer

Cancer Chemother Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Daniel Moj, Nina Hanke, Hannah Britz, Sebastian Frechen, Tobias Kanacher

AAPS J· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis